15 results about "Retinal structure" patented technology

The present application relates to a kind of microglial cell P2Y6R target point inhibitor and its application, belong to biological medicine technical field.For the problems such as lack of effective treatment means for retinal pigment degeneration, abnormal activation of microglial cell accelerates course and lack of specific intervention target point, the application of inhibitor with P2Y6R as target point in preparation treatment retinal pigment degeneration drug is proposed, especially siRNA and shRNA for knocking down microglial cell P2ry6 gene are provided, and AAV vector containing microglial cell specific promoter is constructed, the specific silencing of P2ry6 in retina is realized.The present application can significantly inhibit abnormal activation of microglial cell and inflammatory response, reduce photoreceptor apoptosis, improve retina structure and visual function, and provide a new strategy for targeted treatment of retinal pigment degeneration.

The utility model relates to a kind of delay myopia degree progress and axial growth prevention and control spectacle lens, belong to the field of glasses optics.The lens includes lens base, and the center area is circular center visible area, and outside is peripheral defocus area.Peripheral defocus area is composed of microlens array, and is divided into two asymmetric design regions from central axis: upper half adopts circular ring array structure, and lower half adopts concentric honeycomb array structure.Effective inhibition vision deepens, improve myopia management effect.Peripheral defocus area defocus gradually reduces from center to outside, more fit 8-18 years old teenager eyeball retina structure features.Microlens gap place evenly densely multiple diffusion points, effectively reduce contrast, brightness by soft scattered light, reduce hue difference;Reduce the high contrast signal detected by retina photoreceptor cell and its elongation signal to eye, so as to delay axial growth, delay myopia deepens.

The invention discloses a medicine for treating diabetic retinopathy and application of scorpion venom heat-resistant synthetic peptide in treating the disease, belongs to the field of research and development of polypeptide medicines, and is used for treating or preventing the diabetic retinopathy (DR). Experimental results show that the scorpion venom heat-resistant synthetic peptide (SVHRSP) has the effect of preventing and treating diabetic retinopathy (DR) on a streptozotocin (STZ)-induced mouse experimental diabetes model, and can repress retinal function impairment caused by impairment of streptozotocin (STZ)-induced diabetic mouse retinal photoreceptor cells and retinal nerve inner layer cells; and retina structure damage caused by thinning of the retina thickness of a diabetic mouse induced by STZ (streptozotocin) is inhibited.

The present invention relates to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, in rescuing or restoring retinal function, rescuing or restoring retinal structure, and / or rescuing or restoring choroidal structure and / or function in chronic retinal disorders and other disorders.

A system for coronary artery calcium (CAC) estimation includes a processor and a memory, including instructions stored thereon, which when executed by the processor, cause the system to: extract a plurality of features from patient data using a first machine learning (ML) model, the patient data including a retinal image, sociodemographic data, and / or clinical data; refine the extracted plurality of features using an attention layer, the attention layer configured to highlight retinal structures with an indication of calcification risk; combine a subset of the plurality of features into a data vector using a second ML model; provide a CAC estimation based on the data vector; determine that the provided CAC estimation exceeds a predetermined threshold; and generate an output indicating a calcification risk level, based on the CAC estimation.

The invention belongs to the field of biological medicines, and relates to a new pharmaceutical application of miR-126-3p. The invention discloses application of miR-126-3p or a functional equivalent thereof in preparation of a medicine for preventing or treating retinal structure damage and / or retinal function damage caused by retinal ischemia reperfusion injury caused by retinal artery occlusion. According to the medicine, by supplementing endogenous miR-126-3p consumed in the RIRI process, ganglion cell death can be reduced, and the retina structure can be protected; meanwhile, retina electrophysiological signals can be recovered, the retina function is improved, and therefore the core problem that in the prior art, vision of RAO patients is difficult to recover after blood recanalization is solved.

The invention discloses an SLO, SS-OCT and ERG synchronous ophthalmology multimodal imaging system, and belongs to the field of medical imaging equipment. The system comprises an SLO module, an SS-OCT module, an ERG module, an FPGA main control board and an image processing unit. The FPGA main control board generates a unified hardware clock and a global synchronous trigger signal, controls the three modules to work synchronously based on the same time reference, and adds a unified timestamp to all collected data. And the image processing unit realizes spatial positioning of SS-OCT fault data in an SLO image coordinate system and time sequence alignment of an ERG electrophysiological signal and an SS-OCT scanning position on the basis of the timestamp and a coordinate mapping relation between the SLO and the SS-OCT. According to the method, through hardware-level synchronization and accurate registration, the problem of space-time non-uniformity of multi-modal data is solved, point-to-point fusion of retina structure and function information is realized, and the early diagnosis and evaluation capability of ophthalmic diseases is remarkably improved.

A system for coronary artery calcium (CAC) estimation includes a processor and a memory, including instructions stored thereon, which when executed by the processor, cause the system to: extract a plurality of features from patient data using a first machine learning (ML) model, the patient data including a retinal image, sociodemographic data, and / or clinical data; refine the extracted plurality of features using an attention layer, the attention layer configured to highlight retinal structures with an indication of calcification risk; combine a subset of the plurality of features into a data vector using a second ML model; provide a CAC estimation based on the data vector; determine that the provided CAC estimation exceeds a predetermined threshold; and generate an output indicating a calcification risk level, based on the CAC estimation.

This invention belongs to the field of biotechnology, specifically disclosing a cRGD peptide-functionalized extracellular vesicle derived from mesenchymal stem cells, its preparation method, and its applications. The extracellular vesicle surface is anchored to the cRGD peptide via membrane fusion technology, enabling active targeting and activation of microglia. The preparation method includes isolating and culturing mesenchymal stem cells, purifying natural vesicles by differential ultracentrifugation, and then co-incubating with DSPE-PEG-cRGD for membrane insertion modification. In vitro and in vivo experiments show that the vesicles can be efficiently taken up by activated microglia, delivering endogenous miRNAs, inhibiting the NF-κB pathway, and promoting the transformation of microglia from the M1 to the M2 phenotype. In a retinal ischemia / reperfusion injury model, intravitreal injection of the vesicles reduces retinal ganglion cell apoptosis, protects retinal structure and optic nerve integrity, and restores electroretinogram function. This invention can be used to prepare drugs to alleviate neuroinflammation caused by acute glaucoma.

The invention discloses a ferritin-coupled melanin nano-particle and a preparation method and application thereof, and relates to the technical field of biomedicine, the ferritin-coupled melanin nano-particle AFn-MNP comprises ferritin and a melanin nano-particle, the ferritin and the melanin nano-particle are covalently linked to form a core-shell structure, and the ferritin-coupled melanin nano-particle has excellent iron ion chelating ability and antioxidant activity. The AFn-MNP can effectively remove reactive oxygen species (ROS), inhibit ferroptosis of photoreceptor cells and reverse oxidative damage of retina. In a dry age-related macular degeneration (dAMD) model, single intravitreal injection of AFn-MNP significantly improves the visual function and protects the retina structural integrity. The invention provides a novel nano treatment strategy for treating dAMD and other retinal degenerative diseases.

The invention discloses application of a mesenchymal stem cell exosome-itaconic acid drug delivery system in a nasal delivery preparation for treating retinal artery occlusion, and belongs to the technical field of biological medicines. The drug loading system provided by the invention comprises a mesenchymal stem cell exosome and itaconic acid or itaconic acid derivatives, wherein the itaconic acid or itaconic acid derivatives are encapsulated in the mesenchymal stem cell exosome. According to the exosome and effective compound drug delivery system, dual-effectiveness synergy and superposition of the exosome and the effective compound are achieved, the drug delivery system can effectively relieve damage to a retina structure and a visual function in retina artery occlusion (RAO) through nasal cavity drug delivery, meanwhile, non-invasive rapid drug delivery is effectively achieved, the clinical RAO drug delivery time is shortened, and the drug delivery efficiency is improved. And a time guarantee is provided for good disease prognosis.

The present disclosure provides methods and an apparatus for imaging and analysing images of presumed protein deposits in the retina, retinal tissue or retinal structures and discloses methods differentiating or classifying these deposits and other optical signals from retinal structures into 1) whether they contain or do not contain classes, of proteins or protein deposits called amyloids or other proteins and / or protein deposits related to neurodegenerative eye and brain disease(s); 2) which type(s) of amyloid or other proteins or protein deposits they contain, as well as 3) whether the form and / or properties of the deposit are associated with a class of diseases or with one or another specific condition(s) (or disease(s)); whether or not this is a disease or class of disease associated with the retina or more generally with the nervous system, including the brain or 4) classified as associated with one or another level of severity of condition(s), or disease(s).

This invention belongs to the field of biotechnology and discloses the application of S100A9 inhibitors in the preparation of drugs for treating acute ocular hypertension-induced retinal injury. The study showed that the inflammation scores of AH patients in I / R model mice with APACG were significantly elevated, indicating a marked activation of inflammatory pathways. By comparing differentially expressed mediators, the pro-inflammatory alarmist S100A9 was screened. In vivo experiments confirmed that injection of the S100A9-targeting inhibitor Paquinimod significantly reduced ocular hypertension-induced retinal inflammation, decreased RGC death, and protected retinal structure and function. In vitro experiments confirmed that inhibiting S100A9 expression reduced the levels of inflammatory cytokines in microglia undergoing OGD / R. Furthermore, scRNA-seq analysis confirmed that inhibiting S100A9 upregulated Trem2 expression, thereby providing protection against high IOP-induced retinal injury, suggesting that the S100A9 / TREM2 signaling axis plays a crucial endogenous regulatory role in acute glaucoma-induced retinal neuroinflammation. Inhibition of this signaling axis can produce a neuroprotective effect by inhibiting the excessive activation of retinal microglia.

The invention discloses a conductive polypyrrole nano-composite based on polydopamine modification, a preparation method of the conductive polypyrrole nano-composite and application of the conductive polypyrrole nano-composite in preparation of a medicine for treating retinal ischemia reperfusion injury, and relates to the technical field of biomedical nano-materials. The polydopamine-modified conductive polypyrrole nano-composite forms a core-shell structure through copolymerization of dopamine and pyrrole monomers, and has the properties of oxidation resistance, iron ion chelation, inflammation resistance and conductivity. The nanocomposite can effectively remove active oxygen, inhibit ferroptosis of retinal ganglion cells, regulate polarization of microglial cells to M2 anti-inflammatory phenotype, and recover the endogenous electrophysiological microenvironment of the retina. In a retina ischemia reperfusion injury model, retina structure injury and function loss are remarkably relieved by injecting P-PPy, and good biocompatibility is shown; and a comprehensive and reliable technical route and evaluation standard are provided for application of the nano-composite in preparation of the medicine for treating the retinal ischemia-reperfusion injury.

The present application relates to compositions and methods for rescuing retinal and choroidal structures and functions. The present invention relates to the use of anti-hemi-channel compounds, including anti-connexin 43 hemi-channel open compounds, to rescue or restore retinal function, to rescue or restore retinal structure, and / or to rescue or restore choroidal structure and / or function in chronic retinal disorders and other disorders.